Pluristyx has filed a notice of an exempt offering of securities to raise $14,757,793.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Pluristyx is raising up to $14,757,793.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Pluristyx
Pluristyx is a biotechnology company that provides induced pluripotent stem cells (iPSCs) and expert support to accelerate the development and commercialization of advanced cellular therapies. Its iPSC platform gives clients a single point of access to research- and clinical-grade stem cells, proprietary gene edits, and end-to-end guidance across the product development pathway. The company offers a broad portfolio of non modified and genetically engineered iPSC-based technologies, along with related services, to support customers throughout the entire product lifecycle, from early research through clinical translation and commercialization. By combining high-quality cell lines with specialized genetic engineering and development expertise, Pluristyx positions itself as a comprehensive partner for organizations creating next-generation cell-based therapeutic products.
To learn more, visit https://www.pluristyx.com/
LinkedIn: https://www.linkedin.com/company/pluristyx
Contact:
Benjamin Fryer, Chief Executive Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.